Novo Nordisk Says EU Regulator Approves Updated Wegovy Injection

MT Newswires Live04-09 21:23

Novo Nordisk (NVO) said Thursday that the European Medicines Agency has approved an update to the Wegovy injection's product information, allowing it to be delivered to patients at a controlled temperature of up to 30 degrees Celsius for up to 48 hours.

Previously, the injection had to be kept cold for the entirety of the distribution and delivery process, from where it was made to where it will be used, the company said.

The reduced dependence on cold chain transport is expected to reduce packaging volume and weight as well as potentially lower delivery costs for pharmacies and online partners, Novo Nordisk said.

Shares of Novo Nordisk were down more than 1% in premarket activity Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment